Vaccitech, which develops T cell immunotherapies and vaccines for cancers, COVID-19, and other diseases, raised $111 million by offering 6.5 million ADSs at $17, within the range of $16 to $18.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company utilizes its proprietary platform to develop a broad pipeline of both clinical and preclinical stage therapeutic and prophylactic programs, including VTP-300 for the treatment of chronic hepatitis B infection, VTP-200 for the treatment of HPV, VTP-850 for the treatment of prostate cancer, and VTP-600 for the treatment of non-small cell lung cancer. Current prophylactic programs include VTP-400 for the prevention of shingles, and VTP-500 for the prevention of Middle East respiratory syndrome. Vaccitech has also co-invented a COVID-19 vaccine candidate with the University of Oxford, which was licensed to AstraZeneca.
Vaccitech plans to list on the Nasdaq under the symbol VACC. Morgan Stanley, Jefferies, Barclays and William Blair acted as lead managers on the deal.
